Actinic Keratosis Market Growth Accelerated by Rising Prevalence of Skin Cancer
Actinic keratosis, commonly known as solar keratosis, is a pre-cancerous skin lesion caused by prolonged exposure to ultraviolet (UV) radiation from the sun or indoor tanning. Actinic keratosis treatments help in prevention of skin cancer progression. The wide availability of various treatment options such as photodynamic therapy, topical drugs, cryotherapy, and surgical excision is driving the growth of the actinic keratosis market.
The global actinic
keratosis market is estimated to be valued at US$ 8,070.0 Mn in 2023 and is
expected to exhibit a CAGR of 4.7% over the forecast period 2023 to 2030, as
highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising prevalence of skin cancer due to prolonged exposure to UV radiation
forms one of the key drivers of the actinic keratosis market. According to the
Skin Cancer Foundation, over 4.3 million skin cancers in over 3.3 million
people are diagnosed annually in the U.S. One in five Americans will develop
skin cancer by the age of 70. The increasing awareness regarding early
treatment and diagnosis of pre-cancerous lesions such as actinic keratosis to
prevent progression to skin cancer is expected to drive the demand for actinic
keratosis therapeutics during the forecast period.
The global actinic keratosis market is dominated by lesion-directed therapy segment, which accounts for over 50% market share. The rising preference for non-invasive therapies among patients and the availability of over-the-counter drug products are fueling the growth of this segment. Within lesion-directed therapy, prescription drugs hold the largest share.
Key Takeaways
The global actinic keratosis market is expected to witness high growth over the forecast period. Rapidly growing geriatric population, increasing incidence of skin cancer and easy availability of therapies are some key growth drivers.
Regional analysis: North America currently dominates the global market and is expected to maintain its lead over the forecast years as well. Higher acceptance of advanced therapies, robust healthcare infrastructure and growing aging population are some factors supporting the growth of actinic keratosis market in North America. Europe is projected to be the second largest market driven by rising skin disease burden.
Key players operating in the actinic keratosis market are Almirall, S.A., Bausch Health Companies Inc., Perrigo Company plc., Sun Pharmaceutical Industries Ltd., Hill Dermaceuticals, Inc., Spear Pharmaceuticals, Tolmar Pharmaceuticals, Inc., Bioforntera AG, Cipher Pharmaceuticals Inc., Vidac, Athenex, Inc., 3M, and Mayne Pharma Group Limited. Almirall, S.A and Bausch Health Companies Inc. have leading product portfolio and strong geographic presence supporting their leading positions in the global market.
Comments
Post a Comment